Hemostatic complications after CAR T-cell therapy: linking immunothrombotic mechanisms to phase-adapted management

Hemostatic abnormalities after chimeric antigen receptor (CAR) T-cell therapy range from transient laboratory changes to clinically significant bleeding, venous or arterial thrombosis, disseminated intravascular coagulation (DIC), and thrombotic microangiopathy (TMA). Their interpretation is complicated by overlapping cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), immune effector cell-associated hematotoxicity (ICAHT), immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS), infection, organ dysfunction, and antithrombotic exposure. Clinical and translational evidence indicates that endothelial activation, inflammatory coagulation signaling, altered fibrinolysis, and impaired hematopoietic or hepatic function contribute to heterogeneous hemostatic abnormalities after CAR T-cell therapy. Cytokine-driven endothelial activation and tissue-factor signaling may promote thrombin generation and platelet–leukocyte interactions, while thrombocytopenia, impaired marrow recovery, and fibrinogen depletion reduce hemostatic reserve. In a 100-patient cohort, 51% developed at least one abnormal coagulation parameter; in a separate 127-patient cohort, bleeding and thrombosis occurred in 9.4% and 6.3%, respectively, within three months. Prospective and registry studies have associated bleeding or inflammatory toxicity with baseline hematopoietic reserve, thrombocytopenia, anticoagulant exposure, and changes in platelet and fibrinogen levels. Clinical management requires balancing thrombotic urgency against bleeding risk and hemostatic reserve, with targeted treatment of inflammatory toxicity, individualized anticoagulation, and hemostatic support when indicated. Persistent or recurrent hyperinflammation warrants assessment for IEC-HS, while microangiopathic hemolysis and renal injury should prompt evaluation for TMA rather than automatic attribution to DIC. Prothrombotic inflammatory and endothelial signaling may coexist with reduced hemostatic reserve after CAR T-cell therapy, without following a uniform temporal sequence. Serial laboratory measurements can inform clinical assessment, but their ability to predict bleeding or thrombosis beyond conventional measures remains uncertain. The proposed phase-adapted framework provides a basis for individualized monitoring and management, although its clinical utility, treatment thresholds, and effects on major bleeding and thrombotic outcomes require prospective evaluation.

Authors

Institutions

Publication Details

Journal
Journal of Translational Medicine
Published
2026-11-17
DOI
https://doi.org/10.1186/s12967-026-09251-2
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Hemostatic complications after CAR T-cell therapy: linking immunothrombotic mechanisms to phase-adapted management

Yi Xiao, Xumeng Zhao, Shuai Su, Jiaying Wu
2 links
Journal of Translational Medicine
CAR-T cell therapy research
article

Hemostatic complications after CAR T-cell therapy: linking immunothrombotic mechanisms to phase-adapted management

Yi Xiao, Xumeng Zhao, Shuai Su, Jiaying Wu
article en

Abstract

Hemostatic abnormalities after chimeric antigen receptor (CAR) T-cell therapy range from transient laboratory changes to clinically significant bleeding, venous or arterial thrombosis, disseminated intravascular coagulation (DIC), and thrombotic microangiopathy (TMA). Their interpretation is complicated by overlapping cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), immune effector cell-associated hematotoxicity (ICAHT), immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS), infection, organ dysfunction, and antithrombotic exposure. Clinical and translational evidence indicates that endothelial activation, inflammatory coagulation signaling, altered fibrinolysis, and impaired hematopoietic or hepatic function contribute to heterogeneous hemostatic abnormalities after CAR T-cell therapy. Cytokine-driven endothelial activation and tissue-factor signaling may promote thrombin generation and platelet–leukocyte interactions, while thrombocytopenia, impaired marrow recovery, and fibrinogen depletion reduce hemostatic reserve. In a 100-patient cohort, 51% developed at least one abnormal coagulation parameter; in a separate 127-patient cohort, bleeding and thrombosis occurred in 9.4% and 6.3%, respectively, within three months. Prospective and registry studies have associated bleeding or inflammatory toxicity with baseline hematopoietic reserve, thrombocytopenia, anticoagulant exposure, and changes in platelet and fibrinogen levels. Clinical management requires balancing thrombotic urgency against bleeding risk and hemostatic reserve, with targeted treatment of inflammatory toxicity, individualized anticoagulation, and hemostatic support when indicated. Persistent or recurrent hyperinflammation warrants assessment for IEC-HS, while microangiopathic hemolysis and renal injury should prompt evaluation for TMA rather than automatic attribution to DIC. Prothrombotic inflammatory and endothelial signaling may coexist with reduced hemostatic reserve after CAR T-cell therapy, without following a uniform temporal sequence. Serial laboratory measurements can inform clinical assessment, but their ability to predict bleeding or thrombosis beyond conventional measures remains uncertain. The proposed phase-adapted framework provides a basis for individualized monitoring and management, although its clinical utility, treatment thresholds, and effects on major bleeding and thrombotic outcomes require prospective evaluation.

Journal of Translational Medicine
Tongji Hospital (CN), Huazhong University of Science and Technology (CN)
National Natural Science Foundation of China
Good health and well-being
CAR-T cell therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon